HL
Therapeutic Areas
BeyondSpring Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Plinabulin + G-CSF | Prevention of Chemotherapy-Induced Neutropenia (CIN) | Phase 3 |
| Plinabulin + Docetaxel | Non-Small Cell Lung Cancer (NSCLC) - 2nd/3rd Line | Phase 3 |
| Plinabulin + Radiotherapy & Immunotherapy | Various Solid Tumors (post-ICI failure) | Investigator-Initiated Trials |
Leadership Team at BeyondSpring
LH
Lan Huang, Ph.D.
Co-founder, Chairman & Chief Executive Officer
JL
June Lu, Ph.D.
Chief Scientific Officer
JM
John Mao, Ph.D.
Senior Vice President, Development
HZ
Hao Zhang
Senior Director of Chemical Manufacturing Control (CMC)
JJ
Joy Jia
Vice President, Finance
SX
Sihai Xu, M.B.A.
Director
J(
Jiangwen (Jen) Majeti, Ph.D., M.B.A.
Director